CEL-SCI Corporation
CVM · AMEX
Company research
CEL-SCI Corporation (NYSE American: CVM) is a clinical-stage biotechnology company founded in 1983 and headquartered in Vienna, Virginia, focused on the research and development of immune-based therapies for the treatment of cancer, autoimmune, and infectious diseases. The company's lead immunotherapy candidate, Multikine (Leukocyte Interleukin, Injection), has completed a landmark 928-patient Phase 3 clinical trial — considered the largest ever conducted for head and neck cancer — demonstrating statistically significant survival benefits in a defined target population, and CEL-SCI is currently pursuing regulatory approval outside the U.S. while conducting a 212-patient confirmatory study domestically. In addition to Multikine, CEL-SCI is developing its patented LEAPS (Ligand Epitope Antigen Presentation System) T-cell modulation technology platform, designed to stimulate the immune system against a broad range of conditions including bacterial, viral, and parasitic infections, autoimmune diseases such as rheumatoid arthritis, and various cancers. As a pre-revenue, clinical-stage company led by long-tenured CEO Geert Kersten, CVM funds its operations through equity offerings and carries a market capitalization of approximately $7.9 million.
Research reports
Intellectia’s weekly-updated report assigns CVM a “hold” stance, citing weak financial performance, lack of strong catalysts, and mixed technical signals (slight short-term momentum but longer-term downtrend) as reasons not to take an aggressive position. The analysis highlights zero revenue, worsening EPS, insider buying as a modest positive, and concludes that investors should wait for clearer catalysts or better entry points before buying.
KoalaGains · November 6, 2025CEL-SCI Corporation (CVM) Future Performance Analysis (2026)KoalaGains’ future performance report argues that CVM’s prospects are essentially binary, hinging entirely on a low-probability approval of Multikine after a failed primary Phase 3 endpoint and reliance on subgroup data that regulators rarely accept. It contrasts CVM’s single‑asset, no‑revenue profile with better-capitalized peers, projects multiple dilutive financings, and concludes that the most probable outcome is insolvency, framing any upside scenario as a lottery‑ticket with highly speculative assumptions.
KoalaGains · November 6, 2025CEL-SCI Corporation (CVM) Financial Statement Analysis (2026)This companion report focuses on CVM’s financials, highlighting zero revenue, persistent multi‑million‑dollar quarterly losses, and a balance sheet where approximately USD 1.79 million in cash is outweighed by about USD 9.96 million in debt, leading to a current ratio below 0.5. It underscores chronic negative operating cash flow and reliance on equity issuance to fund operations, warning that repeated dilution, unstable liquidity, and an overleveraged structure create a highly fragile, survival‑mode financial profile for shareholders.
First Berlin Equity Research GmbH · September 1, 2025CEL-SCI Corporation Research Update (01.09.2025)First Berlin’s sell-side research update maintains a BUY rating and cuts its target from USD 186 (post–reverse split basis) to USD 60, arguing that Multikine’s Breakthrough Medicine Designation filing in Saudi Arabia, a partnership with Dallah Pharma, and FDA approval of the confirmatory trial protocol create a pivotal 2025 commercial inflection point. The report acknowledges funding needs and dilution risk but views early Saudi commercialization plus an updated sum‑of‑the‑parts valuation as key catalysts that extend the cash runway into summer 2026 and make CVM a “substantially de‑risked” immuno‑oncology opportunity.